Drug intelligence / Profile preview

TKD peptide

Development stage
Unknown
Lead developer
Multimmune
Modality
Peptides
Administration
Ex Vivo (used For Activating Nk Cells Intended For Adoptive Cell Therapy), In Vitro (experimental)
01

Overview

**TKD peptide** is a synthetic 14-mer peptide corresponding to amino acid residues 450–463 (sequence: TKDNNLLGRFELSG) of the human heat shock protein 70 (Hsp70)[1][7][9]. It acts as a natural killer (NK) cell activator, stimulating both the cytolytic activity and proliferative capacity of NK cells, but only in the presence of low-dose interleukin-2 (IL-2)[1][6][9]. TKD peptide mimics the effect of full-length Hsp70 protein in activating NK cell immune responses, thereby enhancing antitumor activity against Hsp70 membrane-positive tumor cells both in vitro and in vivo[1][5][6][9]. The peptide has been evaluated as a research reagent and in adoptive cell therapies (as an ex vivo NK cell activator) for cancer immunotherapy, particularly for non-small cell lung cancer (NSCLC)[6][8]. It is also explored for immunomodulation in neurodegenerative and stress-related disease research[7].

Brand names
Enkastim-evEnkastim-iv
Other names
Hsp70 TKD peptideHsp-70 TKD peptideHsp 70 TKD peptideHsp70 peptideHsp-70 peptideHsp 70 peptideTKDNNLLGRFELSG
02

Targets

KLRD1 (CD94/NKG2A complex)SLAMF6 (Signaling lymphocytic activation molecule family member 6)NKG2D (Natural killer group 2 member D receptor)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))CD69 (CD69 molecule)

Beyond the preview

Go deeper on TKD peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TKD peptide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call